Abstracts tagged "Disease Activity"

Abstract Number: 0182 • ACR Convergence 2021
Tenderness and Radiographic Progression in Rheumatoid Arthritis and Psoriatic Arthritis
Irina Gessl¹, Mihaela Popescu², Gabriela Supp¹, Martina Durechova¹, Michael Zauner¹, Josef Smolen¹, Daniel Aletaha³ and Peter Mandl¹, ¹Medical University of Vienna, Vienna, Austria, ²Maisonneuve Rosemont Hospital, Longueuil, QC, Canada, ³Medical University Vienna, Vienna, Austria
Background/Purpose: In rheumatoid arthritis (RA) and psoriatic arthritis (PsA), swelling is regarded as a sign of synovitis and is associated with radiographic progression. However, recent…
Abstract Number: 0414 • ACR Convergence 2021
Effect of Induction Therapies on Ear, Nose and Throat Involvement in Anti-neutrophil Cytoplasmic Antibody Associated Vasculitis: Results from a Multi-center Cohort Study
Roline Krol¹, Caroline Schaap¹, Paco Welsing¹, Ruth Klaasen², Hilde Remmelts², Chris Hagen², Franka van Reekum¹, Marloes Heijstek¹ and Julia Spierings¹, ¹University Medical Center Utrecht, Utrecht, Netherlands, ²Meander Medical Center, Amersfoort, Netherlands
Background/Purpose: Up to 87% of patients with anti-neutrophil cytoplasmic antibody (ANCA)- associated vasculitis (AAV) have ear, nose and throat (ENT) involvement, which can lead to…
Abstract Number: 0798 • ACR Convergence 2021
The Impact of Comorbidities on the Simple Disease Activity Index (SDAI) and Its Components over the First Year of Follow-up – an Analysis from the Canadian Early Arthritis Cohort (CATCH)
Lillian-Ruiheng Chen¹, Orit Schieir², Marie-France Valois³, Janet Pope⁴, Susan Bartlett³, Gilles Boire⁵, Glen Hazlewood⁶, Carol Hitchon⁷, Edward C. Keystone⁸, Diane Tin⁹, Carter Thorne¹⁰, Narcisse Singbo¹, Vivian Bykerk¹¹ and Louis Bessette¹², ¹Centre de recherche du CHU de Québec-Université Laval, Québec City, QC, Canada, ²Canadian Early Arthritis Cohort Study, Montréal, QC, Canada, ³McGill University, Montréal, QC, Canada, ⁴University of Western Ontario, London, ON, Canada, ⁵Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁶University of Calgary, Calgary, AB, Canada, ⁷University of Manitoba, Winnipeg, MB, Canada, ⁸Mount Sinai Hospital, Toronto, ON, Canada, ⁹The Arthritis Program Research Group, Newmarket, ON, Canada, ¹⁰Southlake Regional Health Centre, Newmarket, ON, Canada, ¹¹Hospital for Special Surgery, New York, NY, ¹²Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada
Background/Purpose: Comorbid conditions have been shown to negatively influence the achievement of treatment targets in rheumatoid arthritis (RA) patients. The comorbid conditions may bias the…
Abstract Number: 0939 • ACR Convergence 2021
Non-steroidal Anti-inflammatory Drug Use Is Associated with Disease Activity and Reduced Significantly in Patients with Axial Spondyloarthritis Treated with Tumor Necrosis Factor Inhibitors; Data from a Real Life Experience
Elif Ediboglu¹, Dilek Solmaz², Gokhan Kabadayi³, eda otman¹, Haluk Cinaklı¹, Gulay Alp¹, Esra Erpek¹, Sercan Gücenmez⁴, Mustafa Ozmen⁴ and Servet Akar², ¹Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, İzmir, Turkey, ²Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Izmir, Turkey, ³Cigli Education and Research Hospital, İzmir, Turkey, ⁴katip çelebi university, izmir, Turkey
Background/Purpose: Bacground: Non-steroidal anti-inflammatory drugs (NSAIDs) is the first line treatment option in axial spondyloarthritis (axSpA) patients suffering from pain and stiffness. However there is…
Abstract Number: 1244 • ACR Convergence 2021
Mindfulness-Based Stress Reduction (MBSR) to Improve Patient-Related Outcomes (PROs) in Patients with Rheumatoid Arthritis in Clinical Remission but Elevated Negative PROs: A Pragmatic Pilot Study
Marie-Claude Beaulieu¹, Isabelle Gaboury², Patricia L Dobkin³, Nathalie Carrier⁴, France Gervais⁵, Françoise Gendron⁶, Pasquale Roberge⁷, PIERRE DAGENAIS⁷, Sophie Roux⁷ and Gilles Boire¹, ¹Universite de Sherbrooke, Sherbrooke, QC, Canada, ²University of Sherbrooke, Sherbrooke, QC, Canada, ³McGill University, Montréal, QC, Canada, ⁴CIUSSS de l'Estrie - CHUS, Sherbrooke, QC, Canada, ⁵NA, Rimouski, QC, Canada, ⁶NA, Sherbrooke, QC, Canada, ⁷Université de Sherbrooke, Sherbrooke, QC, Canada
Background/Purpose: Many patients with controlled rheumatoid arthritis (RA) continue to report high levels of disease activity (PGA), as well as other disturbing patient-related outcomes (PROs),…
Abstract Number: 1462 • ACR Convergence 2021
Hydroxychloroquine Dose and the Risk of Systemic Lupus Erythematosus Flares
April Jorge¹, Christian Mancini¹, Xiaoqing Fu¹, Gary Ho², Yuqing Zhang³, Karen Costenbader⁴ and Hyon K. Choi⁵, ¹Massachusetts General Hospital, Boston, MA, ²New York University, New York, NY, ³Division of Rheumatology, Allergy, and Immunology, Mass General Hospital, Harvard Medical School, Boston, MA, ⁴Brigham and Women's Hospital, Belmont, MA, ⁵Massachusetts General Hospital, Lexington, MA
Background/Purpose: Hydroxychloroquine (HCQ) is an important treatment for systemic lupus erythematosus (SLE), known to reduce disease activity and flares. To minimize the risk of toxicity,…
Abstract Number: 1777 • ACR Convergence 2021
Association of Opioid Use and Opioid-Related Costs with Patient-Reported Outcomes in Patients with Psoriatic Arthritis or Ankylosing Spondylitis
Alexis Ogdie-Beatty¹, Mark Hwang², Phani Veeranki³, Alexandria Portelli³, Jason Shafrin³, Sofia Pedro⁴, Esther Yi⁵, Steven Hass⁶ and Kaleb Michaud⁷, ¹University of Pennsylvania, Philadelphia, PA, ²McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, ³PRECISIONheor, Los Angeles, CA, ⁴Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ⁵Novartis Pharmaceuticals Corporation, Weehawken, NJ, ⁶H.E. Outcomes, LLC, Los Angeles, CA, ⁷University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Patients with psoriatic arthritis (PsA) or ankylosing spondylitis (AS) experience chronic pain due to inflammatory attributes of their disease. Nonsteroidal anti‑inflammatory drugs and biologics…
Abstract Number: 0209 • ACR Convergence 2021
IgG4 Related Disease: Response to Immunosuppressive Therapy – A Single Centre Retrospective Study in the United Kingdom
Shirish Sangle¹, Neil Morton², Alina Casian², Louise Nel², Jennifer Hannah³ and David D'Cruz⁴, ¹Guy's and St Thomas' Hospital NHS Trust, London, United Kingdom, ²Guys and St Thomas' NHS Trust, London, United Kingdom, ³Kings College Hospital, London, United Kingdom, ⁴Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
Background/Purpose: IgG4 related disease (IgG4-RD) is a rare immune-mediated condition, increasingly being recognised as a multi-organ disorder. It is a relatively new entity and the…
Abstract Number: 0415 • ACR Convergence 2021
Utility of the 22-Item Sinonasal Outcome Test Patient-Reported Outcome Instrument in ANCA-Associated Vasculitis
Ellen Romich, Sherry Chou and Rennie Rhee, University of Pennsylvania, Philadelphia, PA
Background/Purpose: ANCA-associated vasculitis (AAV) causes sinus symptoms that impact quality of life. The 22-item Sinonasal Outcome Test (SNOT-22) is a patient-reported outcome measure to assess…
Abstract Number: 0799 • ACR Convergence 2021
Relationships of Rheumatology Care and Patient Experiences to Rheumatoid Arthritis Remission
Kelly O'Neill¹, Kathryne Marks², Pamela Sinicrope³, Cynthia Crowson⁴, Elena Myasoedova³ and John Davis³, ¹Rheumatoid Patient Foundation, Lutz, FL, ²Rheumatoid Patient Foundation, Boston, MA, ³Mayo Clinic, Rochester, MN, ⁴Mayo Clinic, Eyota, MN
Background/Purpose: Remission is a well-established optimal outcome in rheumatoid arthritis (RA) treatment, yet a minority of patients reach this goal. There is not one recognized…
Abstract Number: 0959 • ACR Convergence 2021
Impact of Systemic Lupus Disease Activity State on Flare Risk After Hydroxychloroquine Maintenance, Reduction or Discontinuation in a Multinational Inception Cohort
Celline Brasil¹, John Hanly², Murray Urowitz³, Ann Clarke⁴, Rosalind Ramsey-Goldman⁵, Caroline Gordon⁶, Michelle Petri⁷, Ellen Ginzler⁸, Daniel Wallace⁹, Sang-Cheol Bae¹⁰, Juanita Romero-Diaz¹¹, Mary Anne Dooley¹², Christine Peschken¹³, David Isenberg¹⁴, Anisur Rahman¹⁵, Susan Manzi¹⁶, Soren Jacobsen¹⁷, S Sam Lim¹⁸, Ronald F van Vollenhoven¹⁹, Ola Nived²⁰, Andreas Jnsen²⁰, Diane Kamen²¹, Cynthia Aranow²², Guillermo Ruiz-Irastorza²³, Jorge Sanchez-Guerrero²⁴, Dafna Gladman²⁵, Paul R Fortin²⁶, Graciela Alarcn²⁷, Joan Merrill²⁸, Kenneth Kalunian²⁹, Manuel Ramos-Casals³⁰, Kristjan Steinsson³¹, Asad Zoma³², Anca Askanase³³, Munther Khamashta³⁴, Ian N. Bruce³⁵, Murat Inanc³⁶ and Sasha Bernatsky³⁷, ¹Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ²Dalhousie University, Halifax, NS, Canada, ³Center for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, Lupus Clinic, Toronto, ON, Canada, ⁴University of Calgary, Calgary, AB, Canada, ⁵Northwestern University, Chicago, IL, ⁶Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ⁷Johns Hopkins University School of Medicine, Baltimore, MD, ⁸SUNY Downstate Health Sciences University, Brooklyn, NY, ⁹Cedars-Sinai, Los Angeles, CA, ¹⁰Hanyang University Medical Center, Seoul, Republic of Korea, ¹¹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de México, Federal District, Mexico, ¹²Raleigh Neurology Associates, Chapel Hill, NC, ¹³University of Manitoba, Winnipeg, MB, Canada, ¹⁴Centre for Rheumatology, University College London, London, United Kingdom, ¹⁵University College London, London, United Kingdom, ¹⁶Allegheny Health Network, Wexford, PA, ¹⁷Rigshospitalet, Copenhagen, Denmark, ¹⁸Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, ¹⁹Amsterdam University Medical Centers, Department of Rheumatology and Clinical Immunology, Rheumatology and Immunology Center ARC, Amsterdam, Netherlands, ²⁰Lund University, Lund, Sweden, ²¹Medical University of South Carolina, Charleston, SC, ²²Feinstein Institutes for Medical Research, Manhasset, NY, ²³Hospital Universitario Cruces, University of the Basque Country, Bizkaia, Spain, ²⁴University Health Network, Toronto, ON, Canada, ²⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ²⁶CHU de Quebec - Universite Laval, Québec City, QC, Canada, ²⁷University of Alabama at Birmingham, Birmingham, AL, ²⁸Oklahoma Medical Research Foundation, Oklahoma City, OK, ²⁹UC San Diego, La Jolla, CA, ³⁰Hospital Clinic, Barcelona, Barcelona, Spain, ³¹National University Hospital of Iceland, Reykjavik, Iceland, ³²University of Glasgow, East Kilbride, United Kingdom, ³³Columbia University Medical Center, New York, NY, ³⁴King's College London, London, United Kingdom, ³⁵University of Manchester, Manchester, United Kingdom, ³⁶Istanbul University Faculty of Medicine, Istanbul, Turkey, ³⁷McGill University, Montréal, QC, Canada
Background/Purpose: Physicians and patients often consider reducing or discontinuing hydroxychloroquine (HCQ) among SLE patients in remission or very low disease activity to limit HCQ-induced toxicity.…
Abstract Number: 1248 • ACR Convergence 2021
Adjusted Analyses of the Benefits of Autoantibody Enrichment on Efficacy Outcomes in Early RA, from a Pooled Analysis of 4 Abatacept RCTs
Janet Pope¹, Sang Hee Park², Mirko Fillbrunn³, Karissa Lozenski², Vadim Khaychuk², Kaleb Michaud⁴, James Signorovitch³, Henry Lane³, Ha Nguyen³ and Philip Conaghan⁵, ¹University of Western Ontario, London, ON, Canada, ²Bristol Myers Squibb, Princeton, NJ, ³Analysis Group, Inc., Boston, MA, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: Previous studies have found differential treatment efficacy of abatacept (ABA) for the treatment of RA based on biomarker-seropositivity.1-4 An earlier study found a differential…
Abstract Number: 1493 • ACR Convergence 2021
Association of the Soluble Terminal Complement Complex C5b-9 (sC5b-9) with Urinary Signs of Kidney Disease in a Swiss SLE Cohort
Kristin Schmiedeberg¹, Ruediger B. Mueller², Thomas Neumann³, Ian Pirker¹, Philipp Rein⁴, Camillo Ribi⁵, Andrea Rubbert-Roth⁶, Michael Kirschfink⁷, Jutta Schroeder-Braunstein⁷, Reinhard Voll⁸ and Johannes von Kempis¹, ¹Kantonsspital St. Gallen, St.Gallen, Switzerland, ²Clinic of Rheumatology, Medical University Hospital Aarau, Aarau, Switzerland, ³Kantonsspital St.Gallen, St.Gallen, Switzerland, ⁴Landeskrankenhaus Hohenems, Wolfurt, Austria, ⁵CHUV, Lausanne, Switzerland, ⁶Kantonspital St Gallen, St.Gallen, Switzerland, ⁷Universitätsklinikum Heidelberg, Heidelberg, Germany, ⁸Department of Rheumatology and Clinical Immunology, University Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany
Background/Purpose: Few reliable laboratory biomarkers exist to determine disease activity in SLE. The role of the soluble terminal complement complex, sC5b-9, in active SLE has…
Abstract Number: 1795 • ACR Convergence 2021
Validation of the Disease Activity Index for Psoriatic Arthritis (DAPSA) with a Quick QuantitativeC-reactive Protein Assay (Q-DAPSA) in Patients with Psoriatic Arthritis (PsA): A Prospective,national, Multicenter Study
Fabian Proft¹, Julia Schally², Henning Christian Brandt³, Jan Brandt-Jrgens⁴, Gerd Burmester¹, Hildrun Haibel⁵, Henriette Käding², Kirsten Karberg⁶, Susanne Lüders⁷, Burkhard Muche², Mikhail Protopopov¹, Judith Rademacher¹, Valeria Rios Rodriguez¹, Murat Torgutalp¹, Maryna Verba⁸ and Silke Zinke⁹, ¹Charité University Medicine Berlin, Berlin, Germany, ²Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Berlin, Germany, ³Praxis für Rheumatologie und Innere Medizin, Berlin, Germany, ⁴Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁵Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁶Praxis für Rheumatologie und Innere Medizin, Berlin, Germany, Berlin, Germany, ⁷Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, Berlin, Germany, ⁸Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Berlin, Germany, ⁹Rheumapraxis Berlin, Berlin, Germany
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous disease with multiple musculoskeletal and dermatological manifestations. Due to this multifaceted clinical appearance, international guidelines do not provide…
Abstract Number: 0235 • ACR Convergence 2021
Are Comorbidities in Patients with Chronic Inflammatory Rheumatic Diseases Associated with Treatment Adherence to Biosimilars in a Non-medical Switch Scenario?
Imke Redeker¹, Stefan Moustakis², Styliani Tsiami², Xenofon Baraliakos², Ioana Andreica², Bjoern Buehring², Juergen Braun² and Uta Kiltz², ¹German Rheumatism Research Centre (DRFZ), Berlin, Germany, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany
Background/Purpose: The availability of biosimilars has created a financial incentive to encourage non-medical switching if cheaper products are on the market. In patients with chronic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].